Skip to content
OpenCapital
Get started

Insulet PODD Debt - Unamortized Discount (Premium) and Issuance Costs, Net

Debt - Unamortized Discount (Premium) and Issuance Costs, Net at other companies

Abbott logo
AbbottABT
$47M-11.3%
Medtronic logo
MedtronicMDT
——
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
——
Viatris logo
ViatrisVTRS
——

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:DeferredFinanceCostsNet.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's debt - unamortized discount (premium) and issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's debt - unamortized discount (premium) and issuance costs, net?
Insulet (PODD) reported debt - unamortized discount (premium) and issuance costs, net of $9.3M in Q1 2026.
How has Insulet's debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
Insulet's debt - unamortized discount (premium) and issuance costs, net decreased by 37.6% year-over-year, from $14.9M to $9.3M.
What is the long-term trend for Insulet's debt - unamortized discount (premium) and issuance costs, net?
Over 5 years (2020 to 2025), Insulet's debt - unamortized discount (premium) and issuance costs, net has grown at a -12.6% compound annual growth rate (CAGR), from $19M to $9.7M.